266 related articles for article (PubMed ID: 31335393)
1. Precision Cancer Trials With Immunomodulatory Agents: Personalizing Histology Agnostic Approaches.
Baretti M; Azad NS
Cancer J; 2019; 25(4):287-295. PubMed ID: 31335393
[TBL] [Abstract][Full Text] [Related]
2. Precision medicine becomes reality-tumor type-agnostic therapy.
Yan L; Zhang W
Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
[TBL] [Abstract][Full Text] [Related]
3. Histology-agnostic drug development - considering issues beyond the tissue.
Pestana RC; Sen S; Hobbs BP; Hong DS
Nat Rev Clin Oncol; 2020 Sep; 17(9):555-568. PubMed ID: 32528101
[TBL] [Abstract][Full Text] [Related]
4. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
5. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
Seligson ND; Knepper TC; Ragg S; Walko CM
Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906
[TBL] [Abstract][Full Text] [Related]
6. Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology.
Tao JJ; Schram AM; Hyman DM
Annu Rev Med; 2018 Jan; 69():319-331. PubMed ID: 29120700
[TBL] [Abstract][Full Text] [Related]
7. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
Adashek JJ; Subbiah V; Kurzrock R
Trends Cancer; 2021 Jan; 7(1):15-28. PubMed ID: 33008795
[TBL] [Abstract][Full Text] [Related]
8. Site-agnostic biomarker-guided oncology drug development.
Jørgensen JT
Expert Rev Mol Diagn; 2020 Jun; 20(6):583-592. PubMed ID: 31813299
[TBL] [Abstract][Full Text] [Related]
9. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
Boyiadzis MM; Kirkwood JM; Marshall JL; Pritchard CC; Azad NS; Gulley JL
J Immunother Cancer; 2018 May; 6(1):35. PubMed ID: 29754585
[TBL] [Abstract][Full Text] [Related]
10. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
11. Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.
Overman MJ; Ernstoff MS; Morse MA
Am Soc Clin Oncol Educ Book; 2018 May; 38():239-247. PubMed ID: 30231358
[TBL] [Abstract][Full Text] [Related]
12. When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age.
Luoh SW; Flaherty KT
Ann Intern Med; 2018 Aug; 169(4):233-239. PubMed ID: 30073297
[TBL] [Abstract][Full Text] [Related]
13. Endometrial cancer: Molecular markers and management of advanced stage disease.
Arend RC; Jones BA; Martinez A; Goodfellow P
Gynecol Oncol; 2018 Sep; 150(3):569-580. PubMed ID: 29843906
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives.
Ciardiello D; Maiorano BA; Parente P; Rodriquenz MG; Latiano TP; Chiarazzo C; Pazienza V; Guerrera LP; Amoruso B; Normanno N; Martini G; Ciardiello F; Martinelli E; Maiello E
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055006
[TBL] [Abstract][Full Text] [Related]
15. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
Janiaud P; Serghiou S; Ioannidis JPA
Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
[TBL] [Abstract][Full Text] [Related]
16. Making precision oncology the standard of care.
The Lancet Oncology
Lancet Oncol; 2017 Jul; 18(7):835. PubMed ID: 28677559
[No Abstract] [Full Text] [Related]
17. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
Tsimberidou AM
Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
[TBL] [Abstract][Full Text] [Related]
18. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
Schmidt KT; Chau CH; Price DK; Figg WD
J Clin Pharmacol; 2016 Dec; 56(12):1484-1499. PubMed ID: 27197880
[TBL] [Abstract][Full Text] [Related]
19. Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design.
Fountzilas E; Tsimberidou AM; Hiep Vo H; Kurzrock R
Cancer Treat Rev; 2024 Apr; 125():102703. PubMed ID: 38484408
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Agnostic Drug Development.
Offin M; Liu D; Drilon A
Am Soc Clin Oncol Educ Book; 2018 May; 38():184-187. PubMed ID: 30231313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
